Protekt Therapeutics

Company Overview

Snapshot

Founded in December 2014 by Prof. Kobi Rosenblum, Protekt Therapeutics operates with 1–10 employees. The company has raised $13.85M across 4 funding rounds from 10 investors. In November 2019, Protekt Therapeutics secured funding from OrbiMed and RMGP Biopharma Investment Fund.

Business overview

Protekt Therapeutics is a biopharmaceutical company focused on identifying and developing potent and selective oral PKR inhibitors (PKRi) to treat cognitive disorders such as Alzheimer's disease and mild cognitive impairment. The company's core technology targets PKR, a stress and proapoptotic kinase, whose inhibition offers a disease-modifying mechanism for modulating key processes in neurodegenerative diseases. Protekt Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and targets patients in the healthcare and life sciences markets.

Strategic signal

In February 2020, news highlighted Protekt Therapeutics' efforts to battle Alzheimer's with an enzyme-busting drug, signaling the company's commitment to addressing significant neurodegenerative diseases. This indicates a focus on advancing its PKR inhibitor technology as a novel therapeutic approach, positioning the company as a potential innovator in the Alzheimer's treatment landscape.

Company Intelligence Q&A

What is Protekt Therapeutics' primary focus?

Protekt Therapeutics is focused on developing a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders like Alzheimer's disease and mild cognitive impairment.

When was Protekt Therapeutics founded?

Protekt Therapeutics was founded in December 2014.

Which investors participated in the November 2019 funding round?

In November 2019, Protekt Therapeutics received funding from OrbiMed and RMGP Biopharma Investment Fund.

What is the significance of PKR inhibition for Protekt Therapeutics?

PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in Alzheimer's Disease and other neurodegenerative diseases, which are central to Protekt Therapeutics' therapeutic strategy.

What was a notable early development for Protekt Therapeutics?

In December 2015, Protekt Therapeutics was established in the FutuRx Incubator, based on technology from Prof. Kobi Rosenblum's lab at Haifa University.